Book Your Slot

Scientific Sessions


Scientific Live appreciates your participation in this Conference. Every Conference is divided into several sessions of subfields. Please select the Subfield of your choice.

Download Abstract template here

Session 1

Alzheimer's Diagnosis and Symptoms

Memory loss that disrupts daily life may be a symptom of Alzheimer's or other dementia. Alzheimer's is a brain disease that causes a slow decline in memory, thinking and reasoning skills. Forgetfulness meaning you forget everything; losing track of important dates, names, and events; forgetting big things and events in life; asking repeatedly for the same information again and again etc. are some of the symptoms that cause Alzheimer's. Diagnosis of symptoms includes tests to assess memory impairment and other thinking skills, judge functional abilities, and identify behavior changes. Other diagnostic tests include Magnetic Resonance Imaging (MRI), Computerized Tomography (CT), and Positron Emission tomography (PET). This session discusses more about Alzheimer's Diagnosis and Symptoms

Session 2

Alzheimer's Clinical Trials

Alzheimer's clinical trials help patients themselves a lot in finding cure for their disease. It helps patients receive regular monitoring by medical professionals; testing new treatments that might work better than those currently available.  However, single clinical trials and studies generally do not have miraculous results, and participants may not benefit directly. With a complex disease like Alzheimer’s, it is unlikely that one drug will cure or prevent the disease. Yet clinical trials for Alzheimer’s disease are must as better preventive methods are applied in such clinical trials. Without clinical trials and research studies and without human volunteers it is near impossible to find cure for dementia and Alzheimer’s disease. This session discusses more about Alzheimer's clinical trials.

Session 3

Alzheimer's Pathophysiology

Alzheimer's disease is pathologically characterized by intracellular neurofibrillary tangles and extracellular amyloidal protein deposits contributing to senile plaques. Over the last two decades, advances in the field of pathogenesis have inspired the researchers for the investigation of novel pharmacological therapeutics centered more towards the pathophysiological events of the disease. While the neuropathological features of Alzheimer's disease are recognized but the intricacies of the mechanism have not been clearly defined. This lack of understanding regarding the pathogenic process may be the likely reason for the non-availability of effective treatment which can prevent onset and progression of the disease. Owing to the important progress in the field of pathophysiology in the last couple of years, new therapeutic targets are available that should render the underlying disease process to be tackled directly. This session discusses more about Alzheimer's pathophysiology.

Session 4

Dementia with Lewy Bodies

Dementia with Lewy bodies is a type of dementia caused by changes in behavior, cognition and movement. Memory loss is not always present early. Dementia steadily worsens over time and the condition is diagnosed when cognitive decline interferes with normal daily functioning. A core feature is REM sleep behavior disorder (RBD), in which individuals lose normal muscle paralysis during REM sleep, and act out their dreams. RBD may appear years or decades before other symptoms. Other frequent symptoms include visual hallucinations; marked fluctuations in attention or alertness; and slowness of movement, trouble in walking, or rigidity. The autonomic nervous system is usually affected, resulting in changes in blood pressure, heart and gastrointestinal function, with constipation as a common symptom. Mood changes such as depression and apathy are common. This session further discusses more about Dementia with Lewy bodies.

Session 5

Frontotemporal Dementia

The frontotemporal dementia (FTD) is of six types involving the frontal or temporal lobes such as behavioral variant of frontotemporal dementia, semantic variant primary progressive aphasia, nonfluent agrammatic variant primary progressive aphasia, corticobasal syndrome, progressive supranuclear palsy, and frontotemporal dementia associated with motor neuron disease.  One variant is the clinical presentation of frontotemporal lobar degeneration, which is characterized by progressive neuronal loss predominantly involving the frontal or temporal lobes, and typical loss of over 70% of spindle neurons, while other neuron types remain intact. Common signs and symptoms include significant changes in social and personal behavior, apathy, blunting of emotions, and deficits in both expressive and receptive language. There is no cure for FTD at present but treatments do help alleviate symptoms. This session discusses more about frontotemporal dementia.

Session 6

Mixed Dementia

Mixed dementia is common among the people suffering with dementia. Mixed dementia is nothing but combination of two or more types of dementia. A number of combinations are possible. For example, some people have both Alzheimer's disease and vascular dementia. Some studies indicate that mixed dementia is the most common cause of dementia in the elderly. For example, autopsy studies looking at the brains of people who had dementia indicate that most people age 80 and older probably had mixed dementia caused by a combination of brain changes related to Alzheimer's disease, vascular disease-related processes, or another neurodegenerative condition. However, in a person with mixed dementia, it may not be clear exactly how many of a person's symptoms are due to Alzheimer's or another disease. This session discusses more about mixed dementia

Session 7

Therapeutic Targets & Mechanisms for Treatment

Recent research findings have led to greater understanding of disease neurobiology in Alzheimer's disease and identification of unique targets for drug development. Current therapeutic options aim at transmitter targets secondary to Alzheimer's disease pathology. The next generation of drugs for Alzheimer's disease will alter the underlying disease course and or provide greater symptomatic benefit. Targets for these drugs were identified in the study of Alzheimer's disease pathophysiology and include molecular events that result in the production and accumulation of the amyloid beta (Aβ) protein in neurotic plaques and hyper phosphorylation, condensation and aggregation of the microtubule-associated protein tau in neurofibrillary tangles (NFTs). This session discusses more about therapeutic targets and mechanisms for treatment.

Session 8

Alzheimer's Disease and Dementia Natural Remedies

Natural remedies for Alzheimer's disease and dementia are dietary changes, lifestyle changes, exercises, yoga and meditation are some of the natural remedies to stop Alzheimer's disease from progressing to a worst form. The dietary supplements have shown some benefit in improving cognitive function and slowing the effects of dementia. Patients can take safe dosages or potential interactions with medications or other supplements. The new study used PET imaging to study the brain for changes and is the first to demonstrate how lifestyle factors directly influence abnormal proteins in people with subtle memory loss who have not yet been diagnosed with dementia. Healthy lifestyle factors also have been shown to be related to reduce shrinking of the brain and lower rates of atrophy in people with Alzheimer's. This session discusses more about Alzheimer's Disease and Dementia Natural Remedies.

Session 9

Causes and Risk Factors

Causes and Risk Factors of Alzheimer's Disease and Dementia are old age, family history, hereditary causes, and other habits such as unhealthy lifestyle.   It has been estimated that up to half of the cases of Alzheimer’s disease worldwide may be the result of seven key modifiable risk factors such as diabetes, head injuries, high blood pressure, obesity, smoking, depression, cognitive inactivity or Low levels of formal education, and lack of physical activity etc. This session discusses more about causes and risk factors causing Alzheimer's disease and dementias.  

Session 10

Awareness and Care Practices

Dementia patients need assistance and full time care as much as drugs. Some common care practices in Dementia are assistance in food and fluid consumption, pain management, social engagement ensuring safety and security of Dementia patients, understanding patient's mood changes, particular behavior, speech problems and help in rectifying them. Main aim of care practices is to ensure cut in hospitalization and psychotropic drugs. Dementia patients need end of life care, so qualified nursing staff is needed. Few care practices which are used are indoor and outdoor activities, visual and audio stimulation, Art therapy. There should be a wide awareness among the public and societies about dementia care practices and awareness. This session discusses more about dementia care practice and awareness.

Session 11

Posterior Cortical Atrophy

Posterior Cortical Atrophy (PCA) is a neurodegenerative condition characterized by progressive, often dramatic and relatively selective decline in visual processing skills and other functions sub-served by parietal, occipital and occipital-temporal regions. Age of onset is typically between 50–65 years and the syndrome is associated with a variety of underlying pathologies. Posterior Cortical Atrophy has been recognized for more than two decades and yet the condition is relatively neglected by researchers. Patients often experience a considerable delay in the time to diagnosis owing to the young age of onset and unusual presenting symptoms. In addition the term PCA has been applied inconsistently, making it difficult to draw comparisons across studies. This session discusses more about Posterior Cortical Atrophy (PCA).

Session 12

Diseases Associated with Dementia

Dementia is a term used to describe severe changes in the brain that causes memory loss. Diseases associated with dementia are many, which include Alzheimer's disease - which is the most common type of dementia; Vascular dementia - which is caused by a lack of blood flow to the brain and can happen as you age and can be related to atherosclerotic disease or stroke; dementia with Lewy bodies - which is caused by protein deposits in nerve cells, this interrupts chemical messages in the brain and causes memory loss and disorientation; Frontotemporal dementia - affect the front and side parts of the brain, which are the areas that control language and behavior; Parkinson's disease, Creutzfeldt-Jakob disease, Wernicke-Korsakoff syndrome and many others. This session discusses more about diseases associated with dementia.

Session 13


Neuroimmunology is a field joining neuroscience, the investigation of the sensory system, and immunology, the investigation of the immune system. Neuroimmunologists look to more readily comprehend the connections of these two complex frameworks amid improvement, homeostasis, and reaction to wounds. A long haul objective of this quickly creating examination zone is to additionally build up our comprehension of the pathology of certain neurological sicknesses, some of which have no reasonable etiology. In doing as such, neuroimmunology adds to the advancement of new pharmacological medications for a few neurological conditions. Numerous kinds of cooperations include both the apprehensive and invulnerable frameworks including the physiological working of the two frameworks in wellbeing and sickness, glitch of either or potentially the two frameworks that prompts issue, and the physical, compound, and ecological stressors that influence the two frameworks every day.

Session 14

Traumatic Brain Injury

Traumatic brain injury (TBI) is an injury having a wide range of symptoms and disabilities. Its effects are devastating on the person and his immediate family members. A brain injury is mild if loss of consciousness and/or confusion and disorientation is less than 30 minutes. MRI and CAT scans may not show anything, but the person may have cognitive problems like headache, mood swings and frustration, difficulty thinking, memory problems, and attention deficits. This session discusses various causes and symptoms, the diagnosis procedures and the treatment for traumatic brain injury.

Session 15

Geriatrics and Cognitive Disorder

Geriatrics is concerned with diseases such as cognitive disorders that occur in older people generally over the age of 60. Geriatrics focuses its attention on such cognitive disorders occurring in old age people over 60 years. Right diagnosis of cognitive disorders is made difficult due to the fact that similar symptoms are associated with old age disorders and diseases. Some of the most common symptoms leading to dementia are difficulty performing tasks, disorientation of time and place, poor judgment, personality changes; becoming irritable, fearful, suspicious, and tremors etc. This session focuses its attention on the studies of Geriatrics and the cognitive diseases and how best they could manage to cure these diseases.

Session 16

Amyloidal protein in Dementia

Amyloid Precursor Protein (APP) proteolysis is the crucial step in the development of Alzheimer’s disease. Alzheimer’s disease (AD) is characterized by the accumulation of the β-amyloid peptide (Aβ) within the brain along with hyperphosphorylated and cleaved forms of the microtubule-associated protein tau. Genetic, biochemical, and behavioral research suggest that physiologic generation of the neurotoxic Aβ peptide from sequential Amyloid Precursor Protein (APP) which is a single-pass transmembrane protein expressed at high levels in the brain. Why Aβ accumulates in the brains of elderly individuals is not clear but could relate to changes in Amyloid Precursor Protein (APP) metabolism or Aβ elimination. Genetic studies and biochemical processes of Amyloid Precursor Protein (APP) is going to be crucial in the development of therapeutic targets to treat Alzheimer’s disease.

Session 17


Neuropharmacology deals with the study of how drugs affect cellular function in the nervous system and the neural mechanisms that impacts behavior. There are two main branches of neuropharmacology, which are behavioral and molecular. Behavioral neuropharmacology focuses on the study of how drugs affect human behavior (neuropsychopharmacology), the drug dependence and addiction affecting the human brain. While molecular neuropharmacology involves the study of neurons and their neurochemical interactions with an overall goal of developing drugs having beneficial effects on neurological function. Both fields are interconnected with the interactions of neurotransmitters, neuropeptides, neurohormones, neuromodulators, enzymes, secondary messengers, co-transporters, ion channels, and receptor proteins in the central and peripheral nervous systems. This session discusses further about the research studies, and the drug development processes that treat many different neurological disorders, including pain, neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease, psychological disorders, addiction, and many others.

Session 18

Brain diseases

The brain is body’s control center. It’s part of the nervous system, which also includes the spinal cord and a large network of nerves and neurons. Together, the nervous system controls everything from your five senses to the muscles throughout your body. When your brain is damaged, it can affect many different things, including your memory, your sensation, and even your personality. Brain disorders include any conditions or disabilities that affect your brain. This includes those conditions that are caused by illness, genetics, or traumatic injury.

Session 19

Parkinson’s diseases

Parkinson's disease (PD) is a chronic and progressive movement disorder, meaning that symptoms continue and worsen over time. Nearly one million people in the US are living with Parkinson's disease. The cause is unknown, and although there is presently no cure, there are treatment options such as medication and surgery to manage its symptoms.

Session 20

Drug Development in Dementia

Dementia is a progressive, irreversible decline in cognition that, by definition, impacts on a patient pre-existing level of functioning. The clinical syndrome of dementia has several aetiologias of which Alzheimer’s disease (AD) is the most common. Drug development in AD is based on evolving pathophysiological theory. Disease modifying approaches include the targeting of amyloid processing, aggregation of tau, insulin signaling, neuroinflammationand neurotransmitter dysfunction, with efforts thus far yielding abandoned hopes and on-going promise. Reflecting its dominance on the pathophysiological stage the amyloid cascade is central to many of the emerging drug therapies.